Skip to main content
SpringerLink
Log in

Collagen Vascular Diseases

  • Chapter
  • First Online:
Therapy in Pediatric Dermatology

  • 1424 Accesses

Abstract

Autoimmune collagen vascular diseases, also referred to as autoimmune connective tissue disorders or rheumatic diseases, are a heterogeneous group of disorders caused by circulating autoantibodies that lead to inflammation of connective tissue throughout the body. Many present with dermatologic findings that may be diagnostic, but also have extracutaneous manifestations. This chapter will focus on rare autoimmune connective tissue diseases in children: Antiphospholipid Antibody Syndrome, Anetoderma, Atrophoderma of Pasini and Pierini, Degos Disease (Malignant Atrophic Papulosis), Dermatomyositis, Eosinophilic Fasciitis, Juvenile Idiopathic, Arthritis, Lupus Erythematosus, Localized Scleroderma/Morphea, Lichen Sclerosus, Mixed Connective Tissue Disease and Relapsing Polychondritis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Notes

  1. 1.

    Reported use only in adults.

References

  1. Avcin T, Cimaz R, Rozman B, P-ARC Group. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus. 2009;18(10):894–9.

    Article  CAS  PubMed  Google Scholar 

  2. Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin N Am. 2007;33(3):499–523.

    Article  Google Scholar 

  3. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, et al. Task force on catastrophic antiphospholipid syndrome (APS) and Non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20(2):165–73.

    Article  CAS  PubMed  Google Scholar 

  4. Cabral M, Abadesso C, Conde M, Almeida H, Carreiro H. Catastrophic antiphospholipid syndrome: first signs in the neonatal period. Eur J Pediatr. 2011;170(12):1577–83.

    Article  CAS  PubMed  Google Scholar 

  5. Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–7.

    Article  PubMed  Google Scholar 

  6. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, et al. Task force on catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS manifestations (II): thrombocytopenia and skin manifestations. Lupus. 2011;20(2):174–81.

    Article  CAS  PubMed  Google Scholar 

  7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

    Article  CAS  PubMed  Google Scholar 

  8. Freeman H, Patel J, Fernandez D, Sharples P, Ramanan AV. Fitting and flailing: recognition of paediatric antiphospholipid syndrome. Arch Dis Child Educ Pract. 2014;99(1):28–36.

    Article  CAS  Google Scholar 

  9. Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, Lirola-Cruz J, Neth O. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics. 2010;125(6):e1523–8.

    Article  PubMed  Google Scholar 

  10. Haskin O, Amir J, Schwarz M, Schonfeld T, Nahum E, Ling G, et al. Severe abdominal pain as a presenting symptom of probable catastrophic antiphospholipid syndrome. Pediatrics. 2012;130(1):e230–5.

    Article  PubMed  Google Scholar 

  11. Veraldi S, Schianchi R. Chickenpox, impetigo, and anetoderma. Pediatr Dermatol. 2006;23(3):305–6.

    Article  PubMed  Google Scholar 

  12. Tammaro A, Narcisi A, Abruzzese C, Cortesi G, Giulianelli V, Parisella FR, et al. Unusual case of linear anetoderma in children. J Dermatol. 2014;41(6):552–3.

    Article  PubMed  Google Scholar 

  13. Hodak E, Feureman H, David M. Primary anetoderma is a cutaneous sign of antiphospholipid antibodies. J Am Acad Dermatol. 2008;58(2):351.

    Article  PubMed  Google Scholar 

  14. Gamo R, Ortíz-Romero P, Sopena J, Guerra A, Rodríguez-Peralto JL, Iglesias L. Anetoderma developing in juvenile xanthogranuloma. Int J Dermatol. 2005;44(6):503–6.

    Article  CAS  PubMed  Google Scholar 

  15. Karrer S, Szeimies RM, Stolz W, Landthaler M. Primary anetoderma in children: report of two cases and literature review. Pediatr Dermatol. 1996;13(5):382–5.

    Article  CAS  PubMed  Google Scholar 

  16. de Souza EM, Daldon PE, Cintra ML. Anetoderma associated with primary antiphospholipid syndrome. J Am Acad Dermatol. 2007;56(5):881–2.

    Article  PubMed  Google Scholar 

  17. Hodak E, David M. Primary anetoderma and antiphospholipid antibodies – review of the literature. Clin Rev Allergy Immunol. 2007;32(2):162–6.

    Article  PubMed  Google Scholar 

  18. Goujon E, Beer F, Gay S, Sandre D, Gouyon JB, Vabres P. Anetoderma of prematurity: an iatrogenic consequence of neonatal intensive care. Arch Dermatol. 2010;146(5):565–7.

    Article  PubMed  Google Scholar 

  19. Maffeis L, Pugni L, Pietrasanta C, Ronchi A, Fumagalli M, Gelmetti C, et al. Iatrogenic anetoderma of prematurity: a case report and review of the literature. Case Rep Dermatol Med. 2014;2014:781493.

    PubMed  PubMed Central  Google Scholar 

  20. Yu HJ, Shin H, Kang MS, Kim JS. A case of primary anetoderma in an infant. Br J Dermatol. 2007;157(6):1267–9.

    Article  PubMed  Google Scholar 

  21. Lee SM, Kim YJ, Chang SE. Pinhole carbon dioxide laser treatment of secondary anetoderma associated with juvenile xanthogranuloma. Dermatol Surg. 2012;38(10):1741–3.

    Article  CAS  PubMed  Google Scholar 

  22. Canizares O, Sachs PM, Jaimovich L, Torres VM. Idiopathic atrophoderma of Pasini and Pierini. AMA Arch Dermatol. 1958;77:42–58. discussion 60.

    Article  CAS  Google Scholar 

  23. Pullara TJ, Lober CW, Fenske NA. Idiopathic atrophoderma of Pasini and Pierini. Int J Dermatol. 1984;23:643–5.

    Article  CAS  PubMed  Google Scholar 

  24. Kim SK, Rhee SH, Kim YC, Lee ES, Kang HY. Congenital atrophoderma of Pasini and Pierini. J Korean Med Sci. 2006;21:169–71.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Handler MZ, Alshaiji JM, Shiman MI, Elgart GW, Schachner LA. Congenital idiopathic atrophoderma of Pasini and Pierini. Dermatol Online J. 2012;18:4.

    PubMed  Google Scholar 

  26. Zhang RZ, Zhu WY. Two uncommon cases of idiopathic atrophoderma of pasini and pierini: multiple and giant. Indian J Dermatol Venereol Leprol. 2011;77:402.

    PubMed  Google Scholar 

  27. Kencka D, Blaszczyk M, Jablonska S. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea. Dermatology. 1995;190:203–6.

    Article  CAS  PubMed  Google Scholar 

  28. Saleh Z, Abbas O, Dahdah MJ, Kibbi AG, Zaynoun S, Ghosn S. Atrophoderma of Pasini and Pierini: a clinical and histopathological study. J Cutan Pathol. 2008;35:1108–14.

    Article  PubMed  Google Scholar 

  29. Buechner SA, Rufli T. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. J Am Acad Dermatol. 1994;30:441–6.

    Article  CAS  PubMed  Google Scholar 

  30. Arpey CJ, Patel DS, Stone MS, Qiang-Shao J, Moore KC. Treatment of atrophoderma of Pasini and Pierini-associated hyperpigmentation with the Q-switched alexandrite laser: a clinical, histologic, and ultrastructural appraisal. Lasers Surg Med. 2000;27:206–12.

    Article  CAS  PubMed  Google Scholar 

  31. Carter JD, Valeriano J, Vasey FB. Hydroxychloroquine as a treatment for atrophoderma of Pasini and Pierini. Int J Dermatol. 2006;45:1255–6.

    Article  PubMed  Google Scholar 

  32. Lee Y, Oh Y, Ahn SY, Park HY, Choi EH. A case of atrophoderma of Pasini and Pierini associated with borrelia burgdorferi infection successfully treated with oral doxycycline. Ann Dermatol. 2011;23:352–6.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Theodoridis A, Konstantinidou A, Makrantonaki E, Zouboulis CC. Malignant and benign forms of atrophic papulosis (Köhlmeier–Degos disease): systemic involvement determines the prognosis. Br J Dermatol. 2014;170(1):110–5.

    Article  CAS  PubMed  Google Scholar 

  34. Torrelo A, Sevilla J, Mediero IG, Candelas D, Zambrano A. Malignant atrophic papulosis in an infant. Br J Dermatol. 2002;146(5):916–8.

    Article  CAS  PubMed  Google Scholar 

  35. Horner FA, Myers GJ, Stumpf DA, Oseroff BJ, Choi BH. Malignant atrophic papulosis (Köhlmeier–Degos disease) in childhood. Neurology. 1976;26(4):317–21.

    Article  CAS  PubMed  Google Scholar 

  36. Shapiro LS, Toledo-Garcia A, Farrell JF, Aixa E. Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil–early experience. Orphanet J Rare Dis. 2013;8(1):52.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Theodoridis A, Makrantonaki E, Zouboulis CC. Malignant atrophic papulosis (Köhlmeier-Degos disease) – A review. Orphanet J Rare Dis. 2013;8:10.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Magro CM, Wang X, Garrett-Bakelman F, Laurence J, Shapiro LS, DeSancho MT. The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet J Rare Dis. 2013;8:185.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015. doi:10.1002/mus.24566 [Epub ahead of print].

    PubMed  Google Scholar 

  40. Rider L, Lindsley C, Cassidy J. Juvenile dermatomyositis. In: Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 375–413.

    Google Scholar 

  41. Hornung T, Wenzel J. Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis. Diagn Treat Drugs. 2014;74(9):981–98.

    CAS  Google Scholar 

  42. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to Juvenile Dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey. J Rheumatol. 2010;37(9):1953–61.

    Article  CAS  PubMed  Google Scholar 

  43. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and rheumatology research alliance consensus conference. Arthritis Care Res. 2012;64(4):546–53.

    Article  Google Scholar 

  44. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498–503.

    CAS  PubMed  Google Scholar 

  45. Dagher R, Desjonquères M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate Mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–6.

    Article  PubMed  Google Scholar 

  46. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate Mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446–51.

    Article  Google Scholar 

  47. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1998;17:221–31.

    Article  Google Scholar 

  48. Grisanti MW, Moore TL, Osborn TG, Haber PL. Eosinophilic fasciitis in children. Semin Arthritis Rheum. 1989;19:151–7.

    Article  CAS  PubMed  Google Scholar 

  49. Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology. 2012;51:557–61.

    Article  CAS  PubMed  Google Scholar 

  50. Loupasakis K, Derk CT. Eosinophilic fasciitis in a pediatric patient. J Clin Rheumatol. 2010;16:129–31.

    Article  PubMed  Google Scholar 

  51. Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology. 2010;49:1184–8.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Smith LC, Cox NH. Dapsone treatment for eosinophilic fasciitis. Arch Dermatol. 2008;144:845–7.

    Article  CAS  PubMed  Google Scholar 

  53. Alonso-Castro L, de Las HE, Moreno C, Fleta-Asín B, Muñoz-Zato E, Carrillo R, Jaén P. Eosinophilic fasciitis/generalized morphea overlap successfully treated with azathioprine. Int J Dermatol. 2014;53:1386–8.

    Article  CAS  PubMed  Google Scholar 

  54. Pimenta S, Bernardes M, Bernardo A, et al. Intravenous immune globulins to treat eosinophilic fasciitis: a case report. Jt Bone Spine. 2009;76:572–4.

    Article  Google Scholar 

  55. Tzaribachev N, Holzer U, Schedel J, et al. Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology. 2008;47:930–2.

    Article  CAS  PubMed  Google Scholar 

  56. Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002–2004). Clin Exp Rheumatol. 2006;24:65–9.

    CAS  PubMed  Google Scholar 

  57. Silny W, Osmola-Mankowska A, Czarnecka-Operacz M, Zaba R, Danczak-Pazdrowska A, Marciniak A. Eosinophilic fascitis: a report of two cases treated with ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed. 2009;25:325–7.

    Article  PubMed  Google Scholar 

  58. Romano C, Rubegni P, De Aloe G, Stanghellini E, D’Ascenzo G, Andreassi L, Fimiani M. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol. 2003;17:10–3.

    Article  CAS  PubMed  Google Scholar 

  59. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.

    PubMed  Google Scholar 

  60. Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches. Clin Epidemiol. 2014;6:379–93.

    PubMed  PubMed Central  Google Scholar 

  61. Calabro JJ, Marchesano JM. Rash associated with juvenile rheumatoid arthritis. J Pediatr. 1968;72(5):611–9.

    Article  CAS  PubMed  Google Scholar 

  62. Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54(11):3564–72.

    Article  PubMed  Google Scholar 

  63. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–512.

    Article  PubMed  Google Scholar 

  64. Cleary AG, Murphy HD, Davidson JE. Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child. 2003;88(3):192–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Methotrexate. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 5 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  66. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992;326(16):1043–9.

    Article  CAS  PubMed  Google Scholar 

  67. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.

    Article  Google Scholar 

  68. Leflunomide. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 6 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  69. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352(16):1655–66.

    Article  CAS  PubMed  Google Scholar 

  70. van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41(5):808–16.

    Article  PubMed  Google Scholar 

  71. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42(11):2325–9.

    Article  CAS  PubMed  Google Scholar 

  72. Sulfasalzine. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 9 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  73. Cyclosporine. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 11 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  74. Tacrolimus. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 11 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  75. Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malattia C, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24(5):599–605.

    CAS  PubMed  Google Scholar 

  76. Tanaka H, Tsugawa K, Suzuki K, Oki ES, Nonaka K, Kimura S, et al. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 2007;166(10):1053–5.

    Article  CAS  PubMed  Google Scholar 

  77. Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y, Inoue N, Yachie A. Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology. 2014;53(11):2120–2.

    Article  PubMed  Google Scholar 

  78. Infliximab. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 12 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  79. Infliximab. In: Pediatric and Neonatal Lexi-drugs online [database on the Internet]. Hudson: Lexicomp, Inc.; 2015 [cited 12 Feb 2015]. Available from: http://online.lexi.com. (Subscription required to view).

  80. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106.

    Article  CAS  PubMed  Google Scholar 

  81. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.

    Article  PubMed  CAS  Google Scholar 

  82. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Etanercept. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 12 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  84. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763–9.

    Article  CAS  PubMed  Google Scholar 

  85. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56.

    Article  CAS  PubMed  Google Scholar 

  86. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90.

    Article  CAS  PubMed  Google Scholar 

  87. Adalimumab. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 12 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  88. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20.

    Article  CAS  PubMed  Google Scholar 

  89. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.

    Article  PubMed  CAS  Google Scholar 

  90. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–89.

    Article  CAS  PubMed  Google Scholar 

  91. Abatecapt. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 12 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  92. Abatacept. In: Pediatric and Neonatal Lexi-drugs online [database on the Internet]. Hudson: Lexicomp, Inc.; 2015 [cited 12 Feb 2015]. Available from: http://online.lexi.com. (Subscription required to view).

  93. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91.

    Article  CAS  PubMed  Google Scholar 

  94. Rituximab. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 18 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  95. Rituximab. In: Pediatric and Neonatal Lexi-drugs online [database on the Internet]. Hudson: Lexicomp, Inc.; 2015 [cited 18 Feb 2015]. Available from: http://online.lexi.com. (Subscription required to view).

  96. Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9):1163–72.

    Article  PubMed  Google Scholar 

  97. Anakinra. In: Pediatric and Neonatal Lexi-drugs online [database on the Internet]. Hudson: Lexicomp, Inc.; 2015 [cited 19 Feb 2015]. Available from: http://online.lexi.com. (Subscription required to view).

  98. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–54.

    Article  CAS  PubMed  Google Scholar 

  99. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129–37.

    Article  PubMed  Google Scholar 

  100. Canakinumab. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 19 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  101. Canakinumab. In: Pediatric and Neonatal Lexi-drugs online [database on the Internet]. Hudson: Lexicomp, Inc.; 2015 [cited 19 Feb 2015]. Available from: http://online.lexi.com. (Subscription required to view).

  102. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406.

    Article  CAS  PubMed  Google Scholar 

  103. Rilonacept. In: Pediatric and Neonatal Lexi-drugs online [database on the Internet]. Hudson: Lexicomp, Inc.; 2015 [cited 19 Feb 2015]. Available from: http://online.lexi.com. (Subscription required to view).

  104. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66(9):2570–9.

    Article  CAS  Google Scholar 

  105. Tocilizumab. In: DRUGDEX System [database on the Internet]. Ann Arbor: Truven Health Analytics; 2015 [cited 19 Feb 2015]. Available from: www.micromedexsolutions.com. (Subscription required to view).

  106. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–95.

    Article  PubMed  CAS  Google Scholar 

  107. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–7.

    Article  PubMed  Google Scholar 

  108. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.

    Article  CAS  PubMed  Google Scholar 

  109. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Yang CH, Chen JY, Lee SC, Luo SF. Successful preventive treatment of congenital heart block during pregnancy in a woman with systemic lupus erythematosus and anti- Sjo ̈gren’s syndrome A/Ro antibody. J Microbiol Immunol Infect. 2005;38(5):365–9.

    CAS  PubMed  Google Scholar 

  111. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009;5(3):139–48.

    Article  PubMed  Google Scholar 

  112. Kuhn A, Ochsendorf F, Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus. 2010;19(9):1125–36.

    Article  CAS  PubMed  Google Scholar 

  113. Cavazzana I, Sala R, Bazzani C, Ceribelli A, Zane C, Cattaneo R, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009;18(8):735–9.

    Article  CAS  PubMed  Google Scholar 

  114. Callen JP. Management of “refractory” skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2005;19(5):767–84.

    Article  PubMed  Google Scholar 

  115. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80.

    CAS  PubMed  Google Scholar 

  116. Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children: clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171–6.

    PubMed  Google Scholar 

  117. Bodemer C, Belon M, Hamel-Teillac D, Amoric JC, Fraitag S, Prieur AM, et al. Scleroderma in children: a retrospective study of 70 cases [French]. Ann Dermatol Venereol. 1999;126:691–4.

    CAS  PubMed  Google Scholar 

  118. Pope JE. Scleroderma overlap syndromes. Curr Opin Rheumatol. 2002;14:704–10.

    Article  PubMed  Google Scholar 

  119. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13.

    Article  PubMed  Google Scholar 

  120. Zulian F, Athreya BH, Laxer R, Nelson AM, de Oliveira SK F, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45:614–20.

    Article  CAS  PubMed  Google Scholar 

  121. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96.

    Google Scholar 

  122. Zulian F, etc. Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614–20.

    Google Scholar 

  123. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011;65(5):925–41.

    Article  CAS  PubMed  Google Scholar 

  124. Beltramelli M, Vercellesi P, Frasin A, Gelmetti C, Corona F. Localized severe scleroderma: a retrospective study of 26 pediatric patients. Pediatr Dermatol. 2010;27(5):476–80.

    Article  PubMed  Google Scholar 

  125. Lo CY, Shyur SD, Chu SH, Huang LH, Kao YH, Lei WT, et al. Juvenile scleroderma: experience in one institution. Asian Pac J Allergy Immunol. 2010;28(4):279–86.

    PubMed  Google Scholar 

  126. Inamo Y, Ochiai T. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate. Pediatr Dermatol. 2013;30(6):e191–3.

    Article  PubMed  Google Scholar 

  127. Harrington CI, Dunsmore IR. An investigation into the incidence of auto-immune disorders in patients with lichen sclerosus and atrophicus. Br J Dermatol. 1981;104(5):563–6.

    Article  CAS  PubMed  Google Scholar 

  128. Murphy R. Lichen sclerosus. Dermatol Clin. 2010;28(4):707–15.

    Article  CAS  PubMed  Google Scholar 

  129. Nelson DM, Peterson AC. Lichen sclerosus: epidemiological distribution in an equal access health care system. J Urol. 2011;185(2):522–5.

    Article  PubMed  Google Scholar 

  130. Das S, Tunuguntla HS. Balanitis xerotica obliterans – a review. World J Urol. 2000;18(6):382–7.

    Article  CAS  PubMed  Google Scholar 

  131. Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet. 1999;353(9166):1777–83.

    Article  CAS  PubMed  Google Scholar 

  132. Sahn EE, Bluestein EL, Oliva S. Familial lichen sclerosus et atrophicus in childhood. Pediatr Dermatol. 1994;11(2):160–3.

    Article  CAS  PubMed  Google Scholar 

  133. Powell J, Wojnarowska F. Childhood vulvar lichen sclerosus: an increasingly common problem. J Am Acad Dermatol. 2001;44(5):803–6.

    Article  CAS  PubMed  Google Scholar 

  134. Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int. 2000;86(4):459–65.

    Article  CAS  PubMed  Google Scholar 

  135. Kiss A, Kiraly L, Kutasy B, Merksz M. High incidence of balanitis xerotica obliterans in boys with phimosis: prospective 10-year study. Pediatr Dermatol. 2005;22(4):305–8.

    Article  PubMed  Google Scholar 

  136. Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad. 1999;41(6):911–4.

    Article  CAS  Google Scholar 

  137. Bercaw-Pratt JL, Boardman LA, Simms-Cendan JS. Clinical recommendation: pediatric lichen sclerosus. J Pediatr Adolesc Gynecol. 2014;27(2):111–6.

    Article  PubMed  Google Scholar 

  138. Edmonds EV, Hunt S, Hawkins D, Dinneen M, Francis N, Bunker CB. Clinical parameters in male genital lichen sclerosus: a case series of 329 patients. J Eur Acad Dermatol Venereol. 2012;26(6):730–7.

    Article  CAS  PubMed  Google Scholar 

  139. Val I, Almeida G. An overview of lichen sclerosus. Clin Obstet Gynecol. 2005;48(4):808–17.

    Article  PubMed  Google Scholar 

  140. Chi CC, Kirtschig G, Baldo M, Lewis F, Wang SH, Wojnarowska F. Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus. J Am Acad Dermatol. 2012;67(2):305–12.

    Article  PubMed  Google Scholar 

  141. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989;16:328–34.

    PubMed  Google Scholar 

  142. Swart JF, Wulffraat NM. Diagnostic workup for mixed connective tissue disease in childhood. Israel Med Assoc J. 2008;10:650–2.

    Google Scholar 

  143. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26:61–2.

    Article  CAS  PubMed  Google Scholar 

  144. Farhey Y, Hess EV. Mixed connective tissue disease. Arthritis Care Res. 1997;10:333–42.

    Article  CAS  PubMed  Google Scholar 

  145. Tsai YY, Yang YH, Yu HH, Wang LC, Lee JH, Chiang BL. Fifteen-year experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010;29:53–8.

    Article  PubMed  Google Scholar 

  146. Mier RJ, Shishov M, Higgins GC, Rennebohm RM, Wortmann DW, Jerath R, et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin N Am. 2005;31:483–96.

    Article  Google Scholar 

  147. Singsen BH, Bernstein BH, Kornreich HK, King KK, Hanson V, Tan EM. Mixed connective tissue disease in childhood. A clinical and serologic survey. J Pediatr. 1977;90:893–900.

    Article  CAS  PubMed  Google Scholar 

  148. Tiddens HA, van der Net JJ, de Graeff-Meeder ER, Fiselier TJ, de Rooij DJ, van Luijk W, et al. Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr. 1993;122:191–7.

    Article  CAS  PubMed  Google Scholar 

  149. Knight A, Weiss P, Morales K, Gerdes M, Gutstein A, Vickery M, et al. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: a cross-sectional study. Pediatr Rheumatol Online J. 2014;12:42.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Hajas A, Szodoray P, Nakken B, Gaal J, Zold E, Lakzik R, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol. 2013;40:1134–42.

    Article  PubMed  Google Scholar 

  151. Hoffman RW, Greidinger EL. Mixed connective tissue disease. In: Tsokos GC, Moreland LW, Kammer GM, Pelletier JP, Martel-Pelletier J, editors. Modern therapeutics in rheumatic diseases. Totowa: Humana Press; 2002. p. 347–57.

    Google Scholar 

  152. Ennis H, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.CD002069.pub4.

    PubMed  Google Scholar 

  153. Rummler S, Althaus K, Maak B, Barz D. A case report of successful treatment with immunoadsorption onto protein A in mixed connective tissue disease in childhood. Ther Apher Dial. 2008;12:337–42.

    Article  PubMed  Google Scholar 

  154. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521–31.

    Article  PubMed  Google Scholar 

  155. Fonseca AR, de Oliveira SK, Rodrigues MC, Aymore IL, Domingues RC, Sztajnbok FR. Relapsing polychondritis in childhood: three case reports, comparison with adulthood disease and literature review. Rheum Int. 2013;33:1873–8.

    Article  Google Scholar 

  156. Belot A, Duquesne A, Job-Deslandre C, Costedoat-Chalumeau N, Boudjemaa S, Wechsler B, Cochat P, Piette J, Cimaz R. Pediatric-onset relapsing polychondritis: case series and systematic review. J Pediatr. 2010;156(3):484–9.

    Article  PubMed  Google Scholar 

  157. Sharma A, Gnanapandithan K, Sharma K, Sharma S. Relapsing polychondritis: a review. Clin Rheum. 2013;32:1575–83.

    Article  Google Scholar 

  158. Terrier B, Aouba A, Bienvenu B, Bloch-Queyrat C, Delair E, Mallet J, Mahr A, Guillevin L. Complete remission in refractory relapsing polychondritis with intravenous immunoglobulins. Clin Exp Rheum. 2007;25:136–8.

    Google Scholar 

  159. Buonuomo PS, Bracaglia C, Compana A, Hachem ME, Diociaiuti A, Insalaco A, Benedetti FD, Testa BC, Cortis E, Vincentiis GCD, Ugazio AG. Relapsing polychontritis: new therapeutic strategies with biological agents. Rheum Int. 2010;30:691–3.

    Article  Google Scholar 

  160. Abdwani R, Kolethekkat AA, Abri RA. Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): first case report. Int J Pediatr Otorhinolaryngol. 2012;76:1061–4.

    Article  PubMed  Google Scholar 

  161. Sarodia SD, Dasgupta A, Mehta AC. Management of airway manifestations of relapsing polychondritis: case reports and review of the literature. Chest. 1999;116:1669–75.

    Article  CAS  PubMed  Google Scholar 

  162. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV, Steen VD, et al. Childhood-onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult-onset disease. J Rheum. 2006;33:1004–13.

    PubMed  Google Scholar 

  163. Zulian F, Cuffaro G, Sperotto F. Scleroderma in children: an update. Curr Opin Rheum. 2013;25:643–50. doi:10.1097/BOR.0b013e3283641f61.

    Article  Google Scholar 

  164. Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin N Am. 2008;34:239–55. doi:10.1016/j.rdc.2007.11.004.

    Article  Google Scholar 

  165. Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al. Systemic sclerosis in childhood: clinical and immunological features of 153 patients in an international database. Arthritis Rheum. 2006;54:3971–8.

    Article  CAS  PubMed  Google Scholar 

  166. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA, Lehman TJ. The PRES/ACR/EULAR provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57:203–12.

    Article  PubMed  Google Scholar 

  167. Foeldvari I. Update on pediatric systemic sclerosis: similarities and differences from adult disease. Curr Opin Rheumatol. 2008;20:608–12. doi:10.1097/BOR.0b013e3283103cfd.

    Article  PubMed  Google Scholar 

  168. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351–8.

    Article  CAS  PubMed  Google Scholar 

  169. Steen VD, Costantino JP, Shapiro AP, Medsger TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–7.

    Article  CAS  PubMed  Google Scholar 

  170. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620–8. doi:10.1136/ard.2008.096677.

    Article  CAS  PubMed  Google Scholar 

  171. Zamora AC, Wolters PJ, Collard HR, Connoly MK, Elicker BM, Webb WR, et al. Use of mycophenylate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102:150–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, University of Washington, 1959 NE Pacific Street, Box 356524, Seattle, WA, 98195-6524, USA

    Lauren B. McCaffrey

  2. Department of Pediatrics, University of Washington, Seattle Children’s Hospital, 4800 Sandy Point Way NE, Seattle, WA, 98105, USA

    Heather A. Brandling-Bennett

  3. Division of Dermatology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Box 356524, Seattle, WA, 98195-6524, USA

    Kate O. Khorsand

  4. Pediatric Rheumatology, Kaiser Permanente Roseville, Eureka Street, Roseville, CA, 95661, USA

    Joy Lynn Mombourguette

  5. Department of Pediatric Allergy, Immunology and Rheumatology, Stanford University, Welch Rd, Stanford, CA, 94305, USA

    Rebecca S. Kunder

  6. Physician, Dermatology, Pediatric Dermatology, Dermatology Medical Group, 2811 Ventura Rd, Oxnard, CA, 93030, USA

    Grace S. Sun

  7. Division of Pediatric Rheumatology, Department of Pediatrics, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA

    Nina T. Washington

  8. Department of Dermatology, University of California San Francisco, 1701 Divisadero Street, 3rd Floor, San Francisco, CA, 94115, USA

    Regina-Celeste Ahmad

  9. Department of Dermatology, University of Washington, Box 356524, 1959 NE Pacific, BB 1353, Seattle, WA, 98195, USA

    Shelley Yang

  10. Division of Dermatology, Department of Medicine, University of Washington, 1959 NE Pacific St. Room BB 1353, Box 356524, Seattle, WA, 98195, USA

    Fan Liu

  11. Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA

    Alexander Fogel

  12. Pediatric Dermatology, Stanford University School of Medicine, 700 Welch Road, Palo Alto, CA, 94304, USA

    Joyce M. C. Teng

Authors
  1. Lauren B. McCaffrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather A. Brandling-Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kate O. Khorsand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joy Lynn Mombourguette
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rebecca S. Kunder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Grace S. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nina T. Washington
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Regina-Celeste Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shelley Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alexander Fogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Joyce M. C. Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heather A. Brandling-Bennett .

Editor information

Editors and Affiliations

  1. Stanford University School of Medicine, Stanford, California, USA

    Joyce M.C. Teng

  2. Stanford University School of Medicine, Stanford, California, USA

    Ann L. Marqueling

  3. Pediatric Dermatology, Joe DiMaggio Children’s Hospital, Hollywood, Florida, USA

    Latanya T. Benjamin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

McCaffrey, L.B. et al. (2017). Collagen Vascular Diseases. In: Teng, J., Marqueling, A., Benjamin, L. (eds) Therapy in Pediatric Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-43630-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43630-2_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43628-9

  • Online ISBN: 978-3-319-43630-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation